Stock Research for INSY


Featured Broker: Ally Invest

Get the due diligence for another stock.


INSY Stock Chart & Research Data

The INSY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INSY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


INSY Due diligence Resources & Stock Charts

The INSY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View INSY Detailed Price Forecast - CNN Money CNN View INSY Detailed Summary - Google Finance
Yahoo View INSY Detailed Summary - Yahoo! Finance Zacks View INSY Stock Research & Analysis -

Stock Analysis

TradeIdeas View INSY Trends & Analysis - Trade-Ideas Barrons View INSY Major Holders - Barrons
NASDAQ View INSY Call Transcripts - NASDAQ Seeking View INSY Breaking News & Analysis - Seeking Alpha
Spotlight View INSY Annual Report - OTC Report View INSY OTC Short Report -
TradeKing View INSY Fundamentals - TradeKing Charts View INSY SEC Filings - Bar Chart
WSJ View Historical Prices for INSY - The WSJ Morningstar View Performance/Total Return for INSY - Morningstar
MarketWatch View the Analyst Estimates for INSY - MarketWatch CNBC View the Earnings History for INSY - CNBC
StockMarketWatch View the INSY Earnings - StockMarketWatch MacroAxis View INSY Buy or Sell Recommendations - MacroAxis
Bullish View the INSY Bullish Patterns - American Bulls Short Pains View INSY Short Pain Metrics -

Social Media Mentions

StockTwits View INSY Stock Mentions - StockTwits PennyStocks View INSY Stock Mentions - PennyStockTweets
Twitter View INSY Stock Mentions - Twitter Invest Hub View INSY Investment Forum News - Investor Hub
Yahoo View INSY Stock Mentions - Yahoo! Message Board Seeking Alpha View INSY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for INSY - Insider Cow View Insider Transactions for INSY - Insider Cow
CNBC View INSY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for INSY - OTC Markets
Yahoo View Insider Transactions for INSY - Yahoo! Finance NASDAQ View Institutional Holdings for INSY - NASDAQ

Stock Charts

FinViz View INSY Stock Insight & Charts - StockCharts View INSY Investment Charts -
BarChart View INSY Stock Overview & Charts - BarChart Trading View View INSY User Generated Charts - Trading View

Latest Financial News for INSY

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose
Posted on Wednesday July 03, 2019

INSYS Therapeutics, Inc. (OTCMKTS:INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose. “The FDA’s acceptance of the NDA for INSYS’ proprietary formulation of a naloxone nasal spray is an important milestone in battling the U.S. opioid epidemic,” said Dr. Venkat Goskonda, chief scientific officer at INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company using proprietary technology and capabilities to develop and commercialize innovative pharmaceutical products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.

Opinion: Medical Marijuana Is a Terrible Investment
Posted on Thursday June 20, 2019

Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.

Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News
Posted on Wednesday June 12, 2019

Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher.Source: Insys TherapeuticsInsys Therapeutics (NASDAQ:INSY) notes that it now has approval from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions. It received this approval on Tuesday, but only just announced the news today.This approval will allow the company to move forward with its Insys Therapeutics bankruptcy plans. This marks a move in the right direction for the company as it looks to use the bankruptcy protection to cover its legacy legal liabilities.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWith the First Day motions approval, Insys Therapeutics will be able to continue operations throughout the bankruptcy process. This includes it continuing to pay employees for their work. It will also let the company keep paying its vendors."This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company's legacy legal liabilities," Andrew Long, CEO of Insys Therapeutics, said in a statement. "I would like to thank our team for their continued hard work and dedication as we move forward with our asset sale process." * 7 Stocks to Buy for the Coming Recession The Insys Therapeutics bankruptcy won't just have the company selling off some of its assets to cover its legal costs. Instead, it will be selling "substantially all" of its assets during the process.INSY stock was up 189% as of noon Wednesday, but is down 96% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for the Coming Recession * 10 Smart Dividend Stocks for the Rest of the Year * 5 Tech Stocks That Are Far Too Risky Right Now As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News appeared first on InvestorPlace.

Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
Posted on Wednesday June 12, 2019

Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.